NCT06013150View on ClinicalTrials.gov

Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

December 15, 2023

Study Completion Date

July 10, 2024

Conditions
Anaphylactic Reaction
Interventions
DRUG

Epinephrine

Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.

DRUG

Placebo

Participant in Part 1 of the study will receive matching doses of placebo

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

De Motu Cordis

INDUSTRY